

Illuminating the path to better health through genetic insights

40th Annual J.P. Morgan Health Care Conference
January 11, 2022

Paul J. Diaz
President and CEO
Myriad Genetics



Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company.

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual and transition reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. Market opportunity figures and growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad's corporate website at www.myriad.com.

Who we are, what we do, and why it matters

Illuminating the path to better health through genetic insights.

Our purpose-led Mission

We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us.

Our Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.

Empowering patients with answers and insights for better health

What's my risk of breast cancer?

3 million **MyRisk™** patients
Hereditary Cancer Test

How can I learn more about my baby's health during pregnancy?

2.1 million **Prequel®** + **Foresight®** patients
Prenatal Screen Carrier Screen

















Why isn't my antidepressant working?

1.7 million **GeneSight®** patients
Mental Health Medication Test

How can I beat this cancerous tumor?

150,000 **MyChoice® CDx** + **Prolaris®** patients
Myriad HRD Companion Diagnostic Test Prostate Cancer Prognostic Test

Three focused businesses primed for growth

	 Mental Health	 Women's Health	 Oncology
Business	Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs.	Serving women of all ancestries, assessing risk of cancer and offering prenatal testing solutions.	Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs & treatments.
Market*	\$5B U.S. Market Growing 15%	\$4B U.S. Market Growing 10%	\$4B U.S. Market Growing 8%
Products	 Mental Health Medication Test 	 Hereditary Cancer Test  Carrier Screen  Prenatal Screen  	 Hereditary Cancer Test  Myriad HRD Companion Diagnostic Test  Breast Cancer Prognostic Test  Molecular Profile Test  Germline Companion Diagnostic Test  Prostate Cancer Prognostic Test
Operating Results	Q3 '21 volume: 72,110 Q3 '21 revenue: \$24.1M	Q3 '21 volume: 110,141 Q3 '21 revenue: \$59.1M	Q3 '21 volume: 47,829 Q3 '21 revenue: \$76.8M

* Based upon company and industry research

Transformation and growth strategy

Strategic priorities

A trusted, differentiated partner with specialized expertise



Innovation that improves clinical outcomes, ease of use, and access

Developing and enhancing best-in-class products to support growth, improve patient and provider experience and reach more patients of all backgrounds

Enterprise capabilities to accelerate growth and scale to market opportunity

Investing in tech-enabled commercial tools to drive engagement, improve revenue cycle management, reduce complexity and cost

Focus on execution and delivery of consistent results

Disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability

Executing our transformation plan, on track to accelerate growth

2H CY20

CY21

CY22

Build culture of service excellence, prioritize innovation, reduce complexity and cost

1 Reset the base

- ✓ Launched transformation plan
- ✓ Redefined brand and mission
- ✓ Developed new commercial model
- ✓ Eliminated all outstanding debt
- ✓ Recovered test volumes

2 Elevate current portfolio to full potential

- ✓ Debuted new brand and marketing strategy
- ✓ Reinvested and restructured sales force
- ✓ Enhanced reimbursement and revenue cycle management
- ✓ Initiated steps to fulfill commitment to ESG, including diversity, equity and inclusion
- ✓ Launched new products and offerings
 - MyRisk™ with RiskScore® for all ancestries
 - GeneSight® Psychotropic
 - MyGeneHistory™ 3.0

3 Accelerate growth

- ✓ Build commercial capabilities to support new products and offerings
- ✓ Launch new enterprise commercial model
- ✓ Further develop direct-to-consumer channels
- ✓ Launch unified ordering portal
- ✓ Roll out 'Lab of the Future' – new sequencing technologies
- ✓ New investments in tech, IS infrastructure
- ✓ Strategic partnerships and acquisitions

Mental Health

Addressing the U.S. mental health crisis and need for medication testing



Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

Market

\$5B U.S. Market | Growing 15%

Business

Mark Verratti – President
Q3 '21 revenue: \$24.1M

1.7M+ people tested to date
7 clinical studies published

GeneSight®

Mental Health Medication Test

Elevating GeneSight® to full potential


- GeneSight volumes growing in key provider segments, including primary care, nurse practitioners
- 95% of providers order through online portal
- 10-15% of business originates from digital marketing efforts
- 30% of kits are home-based tests
- Exploring new partnerships in neurology to develop tests for early detection and treatment of Alzheimer's





Commercial model driving lead generation, conversion in mental health

GeneSight[®]
Mental Health Medication Test





Commercial model continues to drive new users

GeneSight®


Mental Health Medication Test

Key drivers

- Virtual patient testing capabilities
- Online ordering
- GeneSight@Home
- Text and email messaging
- Comprehensive mental health test, including ADHD

Volume

Growing at >20% CAGR



Women's Health



Serving healthcare providers and the women who rely on them



Women's Health

Leading health and wellness with best-in-class genetic insights for women of all ancestries, assessing risk of cancer and offering prenatal testing solutions.

Market

\$4B U.S. Market | Growing 10%

Business

Melissa Gonzales – President
Q3 '21 revenue: \$59.1M

Working to launch a version of GeneSight® test for women with postpartum depression

2021 Launch

MyRisk™ | with RiskScore®
Hereditary Cancer Test for all ancestries

5-year and lifetime breast cancer risk assessment

- Only test of its kind for women of all ancestries
- 56% of women qualify for medical management (vs. 10% with standard hereditary cancer test)



2023 Launch

FirstGene™
Comprehensive Prenatal Screen

Combination noninvasive prenatal screening + carrier screening

Only 1 out of 3 patients undergo carrier screening and NIPS during a pregnancy



Unmet need to simplify process



Comprehensive assessment with a single blood draw



Key product enhancement – personalized breast cancer risk for *all* women

New in 2021

MyRisk™
Hereditary Cancer Test

with RiskScore®
for all ancestries

The first and only hereditary cancer test incorporating genetic markers for patients without a high-risk gene mutation

35 hereditary cancer genes + Personal & family history = Tyrer-Cuzick

+ Breast cancer genetic risk markers + Ancestry genetic markers = RiskScore®

Ancestry-informative genetic markers are used to calibrate breast cancer risk

- Only Myriad provides genetically-informed breast cancer risk assessment as part of a comprehensive panel, with equity in care for all patients
- Closing the gap between women who meet NCCN guidelines for MyRisk and do not have European ancestry with those who do





Combined prenatal test simplifies and advances prenatal patient care

New - early 2023

FirstGene™


Comprehensive Prenatal Screen



Advantages

- Early insight into recessive disease status
- Increased sensitivity for all pregnancies
- Eliminates unnecessary amniocentesis
- Single maternal (no paternal) blood draw

Simplified Workflow



* Scheduled for launch in 2023. Diagnostic test like amniocentesis still recommended as follow-up confirmation for a positive result. FirstGene provides insight into recessive status of the fetus in a screening modality

Oncology





Providing answers that guide cancer treatment decisions



Oncology

Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs and treatments.

Market

\$4B U.S. Market | Growing 8%

Business

Faith Zaslavsky – President
Q3 '21 revenue: \$76.8M

MyRisk™
Hereditary Cancer Test

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

EndoPredict®
Breast Cancer Prognostic Test

New
Precise™ Tumor
Molecular Profile Test

BRACAnalysis CDx®
Germline Companion Diagnostic Test


Prolaris®
Prostate Cancer Prognostic Test

- Combining strength in germline/hereditary cancer testing and companion diagnostics
- Expanding across care continuum with suite of offerings in one convenient, differentiated experience that provides oncologists with the single service they want
- Building market-leading companion diagnostics portfolio – extending beyond ovarian to breast, prostate, and pancreatic cancer
- Plan to expand portfolio into Liquid Bx treatment and Liquid Bx MRD





Molecular diagnostics across the continuum of cancer care



Working to expand portfolio into Liquid Bx therapy selection and Liquid Bx MRD



A differentiated, comprehensive solution for advanced precision oncology

New

Precise™

Oncology Solutions


MyRisk™
Hereditary Cancer Test

+

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

+

New
Precise™ Tumor
Molecular Profile Test



Launching this quarter

Helping providers determine the best treatment plan – clear, integrated, personalized


- Partnering with Intermountain Healthcare and Illumina to become the only lab with combination of:
 - World-class germline testing (MyRisk™ / BRACAnalysis CDx®)
 - HRD “Gold Standard” (MyChoice® CDx)
 - Best-in-class Comprehensive Genetic Tumor Panel (Illumina’s TS0500 / Precise™ Tumor)
- Helping patients understand cancer genetics and if it affects their family



MyChoice[®] CDx

Myriad HRD Companion Diagnostic Test

- Market leading expertise with BRACAnalysis CDx and novel, patented homologous DNA-repair deficiency (HRD) test, MyChoice CDx
- MyChoice CDx recently approved by US, European and Japanese regulatory agencies to predict response to PARP-inhibitors (PARPi's) in ovarian cancer
- Expanding MyChoice CDx into indications beyond ovarian cancers:
 - Currently being tested in more than a dozen clinical trials, including patients with breast, prostate, pancreatic and other cancer types
 - Approval to use MyChoice CDx in breast, prostate and pancreatic cancer represents an opportunity to expand MyChoice market by ~8X



Total addressable market opportunity

Ovarian Cancer
\$300M / year

Breast, Prostate, Pancreatic Cancers
\$2B / year



Simplifying treatment decisions for men with prostate cancer

Prolaris[®]

Prostate Cancer Prognostic Test

Market leading tumor mRNA expression test that directly measures tumor cell growth – helps identify how prostate cancer is behaving and what treatment options will be most effective in fighting it.



Operating Results

25% Test volume growth in Q3 2021 YOY


2X Revenue growth in Q3 2021, from ~\$6.4M to ~\$12.9M

Key Growth Drivers

- ~250K men diagnosed with prostate cancer / year, 2nd most common cancer
- \$900M total addressable market – only 25% penetrated
- Medicare and commercial coverage expanded to ALL risk patients with localized prostate cancer
- Myriad is the only lab offering both germline testing (MyRisk, BRACAnalysis CDx) + biomarker analysis of tumor (Prolaris)



Roadmap to expanding Myriad's oncology portfolio



Accelerating new commercial capabilities

Scaling our enterprise commercial and tech capabilities

800

sales, medical, and customer service team members

95%

of payers cover Myriad testing in network

60,000+

active ordering clinicians

\$50M+

tech investment to drive volume and improve customer engagement

\$12M+

enterprise commercial and marketing capabilities

Competitive intelligence and market planning

Product/channel management


Brand management and marketing

Tech-enabled customer experience

Sales operations and performance management

600+ EMR integrations and new unified ordering portal

High potential, innovative products




Investing in direct-to-consumer demand generation – promising early results



3-year goal

>1 million qualified consumer leads for multiple products through patient-initiated testing




Q3 '21 results: Qualified lead conversion up > 28% and growing through telemedicine + direct kit shipment

Customized end-to-end solutions for easy customer experience

Myriad Complete™

Suite of services and workflow solutions

- Simplifies genetic testing through patient and provider support at every step
- Seamlessly integrates into clinic workflow
- Saves time and streamlines workflow
- Customizable based on clinic needs




**Stabilizing business and
driving sustainable growth**

Myriad continues to stabilize business and improve operating and financial results

Financial highlights

- Restored same-store growth
- Improved gross margins and profitability through disciplined expense controls
- Returned \$400M to balance sheet through divestitures and improved revenue cycle management
- Expect to enter 2022 with ~\$400M cash and no debt



Q3'21 YoY volume:
+20%

Q3'21 YoY revenue:
+27%

*excludes divested assets

Expect organic revenue growth to accelerate in 2022 going into 2023 through improved sales and marketing execution, product and technology innovation

 **9-12%** estimated organic revenue growth '22-'24

1

MyRisk stabilization

- RiskScore for all ancestries
- Streamlined ordering and billing services, EMR integration
- Direct-to-consumer channel

2

+4-5%

Mental Health

GeneSight® momentum

3

+3-4%

Women's Health

FirstGene™ -- Combined Prequel and Foresight product launch

Expanded medical association guidelines

4

+2-3%

Oncology

Precise™ oncology solution launch

MyChoice™ CDx expansion

Prolaris® momentum

5

Accelerating growth rate in '24+

Upside

- New oncology solutions including liquid biopsy and MRD
- Women's Health product and channel expansion
- Companion diagnostics expansion of indications and pharma partnerships
- M&A / strategic partnerships

Myriad Genetics 2022 financial guidance


	Guidance	Key Assumptions
Revenue*	\$670-\$700	8% - 13% growth from 2021 baseline that <u>excludes</u> divested assets and positive cash collections from prior period orders
Gross Margin %	70% - 72%	Gross margins impacted by benefits from lab efficiencies and automations offset by increasing supply costs & wage inflation
Adjusted Operating Expenses*	\$470 - \$480	Operating expenses impacted by investments in technology, commercial tools, R&D as well as inflationary pressures
Adjusted EPS	\$0.00 - \$0.20	

*In millions

Investment considerations: Myriad strengths and strategic advantages

Leader in genetic testing and precision medicine

- Transformation and growth strategy on track
- Broad and growing commercial capabilities with 60K healthcare providers ordering Myriad products across Women's Health, Oncology and Mental Health
- Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities
- Trusted, differentiated healthcare partner with specialized expertise



Q&A



Appendix

– Third quarter 2021 operating and financial results



Third quarter operating and financial results were strong, despite COVID-19 headwinds and typical seasonal softness

1

Total revenue of **\$167.3M** increased **15% YOY**

Excluding the impact of the divested Vectra, RBM and myPath businesses, quarterly revenue increased **27% YOY**

2

Diagnostic test volumes of **252,000** increased **15% YOY**.

Stability in ASPs for past four quarters, excluding impact of out-of-period collections

3

GAAP total operating expenses were **\$199.4 million**; adjusted total operating expenses decreased **\$1.6 million** sequentially to **\$121.5 million**

4

GAAP operating loss in the quarter was **(\$79.9) million**; adjusted operating loss was **(\$1.4) million**

5

GAAP EPS of **\$0.30**; Adjusted EPS were **(\$0.02)**, and we remain on track to return to profitability in 2022

Closed divestiture of Myriad Autoimmune (Vectra) business
Paid down revolving credit facility - \$413.6 million cash, cash equivalents and investments

Consolidated quarterly highlights

Revenue, adjusted gross margin, adjusted operating income, adjusted EPS

<i>In millions</i>	Quarter ended		
	September 2021	June 2021	September 2020
Revenue	\$167.3	\$189.4	\$145.2
Sequential change	(12%)	9%	—
Adjusted gross margin	71.7%	72.1%	69.8%
Sequential change	-40 bp	+70 bp	—
Adjusted op income (loss)	(\$1.4)	\$13.5	(\$12.3)
Sequential change	(\$14.9)	+\$16.8	—
Adjusted op income (loss)	(\$0.02)	\$0.12	(\$0.15)
Sequential change	(\$0.14)	+\$0.18	—
Revenue from prior period collections	\$8	\$13	(\$2)

Third quarter 2021 — revenue by product

Three months ended September 30

<i>In millions</i>	2021					2020					% Change
	Women's Health	Oncology	Mental Health	Other	Total	Women's Health	Oncology	Mental Health	Other	Total	
Hereditary cancer	\$35.5	\$43.9	—	—	\$79.4	\$39.2	\$41.3	—	—	\$80.5	(1%)
Tumor profiling	—	32.9	—	—	32.9	—	17.0	—	—	17.0	94%
Prenatal	23.6	—	—	—	23.6	16.6	—	—	—	16.6	42%
Pharmacogenomics	—	—	24.1	—	24.1	—	—	11.9	—	11.9	103%
Autoimmune	—	—	—	7.3	7.3	—	—	—	9.1	9.1	(20%)
Other	—	—	—	—	—	—	—	—	0.6	0.6	(100%)
Total molecular diagnostic revenue	59.1	76.8	24.1	7.3	167.3	55.8	58.3	11.9	9.7	135.7	23%
Pharmaceutical and clinical service revenue	—	—	—	—	—	—	—	—	9.5	9.5	(100%)
Total revenue	\$59.1	\$76.8	\$24.1	\$7.3	\$167.3	\$55.8	\$58.3	\$11.9	\$19.2	\$145.2	15%

Revenue and test performance

Year-over-year change September 2020-September 2021

		Revenue	Test Volume
Hereditary cancer	BRACAnalysis [®] CDx Companion Diagnostic Test MyRisk [™] Hereditary Cancer Test	(1%)	0%
Prenatal	Foresight [®] Carrier Screen Prequel [®] Prenatal Screen	42%	7%
Tumor profiling	MyChoice [®] CDx HRD Companion Diagnostic Test EndoPredict [®] Breast Cancer Prognostic Test Prolaris [®] Prostate Cancer Prognostic Test	94%	33%
Pharmacogenomics	GeneSight [®] Mental Health Medication Test	103%	71%
Overall company		15%	15%
Overall company (excluding divestitures)		27%	20%

ASP Stable

